J 2024

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

LUEBKE, Johannes, Alicia SCHMID, Deborah CHRISTEN, Hanneke N G Oude ELBERINK, Lambert F R SPAN et. al.

Základní údaje

Originální název

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Autoři

LUEBKE, Johannes, Alicia SCHMID, Deborah CHRISTEN, Hanneke N G Oude ELBERINK, Lambert F R SPAN, Marek NIEDOSZYTKO, Aleksandra GORSKA, Magdalena LANGE, Karoline V GLEIXNER, Emir HADZIJUSUFOVIC, Alex STEFAN, Irena ANGELOVA-FISCHER, Roberta ZANOTTI, Massimiliano BONIFACIO, Patrizia BONADONNA, Khalid SHOUMARIYEH, von Bubnoff NIKOLAS, Sabine MUELLER, Cecelia PERKINS, Chiara ELENA, Luca MALCOVATI, Hans HAGGLUND, Mattias MATTSSON, Roberta PARENTE, Judit VARKONYI, Anna Belloni FORTINA, Francesca CAROPPO, Knut BROCKOW, Alexander ZINK, Christine BREYNAERT, Toon LEVEN, Akif Selim YAVUZ, Michael DOUBEK (203 Česká republika, domácí), Vito SABATO, Tanja SCHUG, Karin HARTMANN, Massimo TRIGGIANI, Jason GOTLIB, Olivier HERMINE, Michel AROCK, Hanneke C KLUIN-NELEMANS, Jens PANSE, Wolfgang R SPERR, Peter VALENT, Andreas REITER a Juliana SCHWAAB

Vydání

Blood advances, AMSTERDAM, ELSEVIER, 2024, 2473-9529

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 7.500 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001252795100001

Klíčová slova anglicky

systemic mastocytosis; serum chemistry profiling

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 8. 2024 13:35, Mgr. Tereza Miškechová

Anotace

V originále

Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most speci fic serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, beta 2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P < .001). With regard to subvariants of AdvSM, an elevated LDH of >= 260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P < .001; monocytosis, r = 0.26, P < .001) and the presence of an associated myeloid neoplasm (P < .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308 mu g/L vs 146 mu g/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to beta 2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; >= 1.5 points, 1.7 years; P < .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry pro filing is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.